Influenza virus vaccine quadrivalent - Sinovac Biotech
Alternative Names: QIV- Sinovac Biotech; Quadrivalent influenza vaccine - Sinovac Biotech; Sinovac-QIVLatest Information Update: 30 Dec 2024
At a glance
- Originator Sinovac Biotech
- Developer Pontifical Catholic University of Chile; Sinovac Biotech
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 23 May 2024 Sinovac Biotech completes a phase III trial for Influenza (Prevention, In infants, In children) in China (IM) (NCT06049927)
- 16 Sep 2023 Sinovac Biotech initiates a phase III trial for Influenza (Prevention, In infants, In children) in China (IM) (NCT06049927)
- 16 Sep 2023 Sinovac Biotech plans a phase III trial in Influenza virus infections (Prevention, In infants, In children) in China (IM) in September 2023 (NCT06049927)